Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies by C. Dang and co-authors describe new findings in breast cancer
December 25th, 2008
"We conducted a pilot study of dose-dense epirubicin/cyclophosphamide (EC) x 6 -> paclitaxel (P) x 6 with pegfilgrastim. A previous dose-dense trial of FEC (5-fluorouracil [5-FU]/EC) x 6 with filgrastim -> by weekly paclitaxel alternating with docetaxel x 18 was not feasible because of pneumonitis (with dose-dense FEC) and pericardial/pleural effusion (taxane phase)," researchers in the United States report. "Dose-dense EC (without the 5-FU) is not associated with pneumonitis, and dose-dense paclitaxel (alone) is feasible. Primary objective was feasibility. Patients with resectable breast cancer were enrolled, regardless of surgery status, tumor size, or nodal...
Source: Women's Health Weekly (2008-12-25)
|
